Onsdag 12 Mars | 12:05:37 Europe / Stockholm

Kalender

Est. tid*
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-10 08:00 Kvartalsrapport 2025-Q2
2025-05-07 N/A X-dag ordinarie utdelning GENT 0.40 NOK
2025-05-07 08:00 Kvartalsrapport 2025-Q1
2025-05-06 N/A Årsstämma
2025-02-12 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-30 - X-dag ordinarie utdelning GENT 0.00 NOK
2024-04-30 - Kvartalsrapport 2024-Q1
2024-04-29 - Årsstämma
2024-02-09 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning GENT 0.00 NOK
2023-05-05 - Kvartalsrapport 2023-Q1
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning GENT 0.00 NOK
2022-05-18 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-21 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning GENT 0.00 NOK
2021-05-04 - Årsstämma
2021-04-16 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-10-29 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning GENT 0.00 NOK
2020-05-14 - Årsstämma
2020-04-24 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-21 - Extra Bolagsstämma 2019
2019-05-10 - X-dag ordinarie utdelning GENT 0.00 NOK
2018-07-13 - Extra Bolagsstämma 2018
2018-06-13 - X-dag ordinarie utdelning GENT 0.00 NOK
2018-02-27 - Bokslutskommuniké 2017
2017-06-06 - Årsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett medicinskt diagnostikbolag som utvecklar och tillverkar in vitro diagnostiska reagenser för högkapacitetsanalysatorer. Gentians expertis och fokus ligger inom homogena immunanalyser, speciellt infektioner, inflammationer, njursvikt och kongestiv hjärtsvikt. Bolagets huvudkontor och produktionsanläggningar finns i Moss, Norge, och betjänar den globala human- och veterinärdiagnostikmarknaden genom försäljnings- och representationskontor i nyckelländer.
2025-03-10 12:44:14
Moss,10 March 2025

Gentian Diagnostics is pleased to announce the launch of the GCAL® Calprotectin
Immunoassay with Beckman Coulter Diagnostics to its clinical chemistry
platforms. This collaboration illustrates our commitment to enhance diagnostic
efficiency for improved treatment decisions.

The Gentian GCAL® Calprotectin Immunoassay enables precise measurement of
calprotectin in human plasma and serum. Circulating calprotectin is widely
recognized as a sensitive biomarker for detection and assessment of inflammation
across a broad range of diseases. This makes it a valuable tool in numerous
inflammatory and rheumatic diseases as well as in detection and risk assessment
of the inflammatory response in infections, highlighting its broad utility in
clinical practice.

"We are pleased to officially announce that Beckman Coulter Diagnostics, a
leader in the field of clinical diagnostics, is launching our GCAL® assay," says
Matti Heinonen, CEO of Gentian Diagnostics. "This partnership builds on our
long-standing relationship with Beckman Coulter and marks a significant
milestone in our commitment to advancing market development for circulating
calprotectin. By combining our innovative GCAL® assay with Beckman Coulter's
industry expertise and reach, we are poised to empower healthcare professionals
with more accurate and timely diagnostic tools, enhancing patient care and
outcomes."

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analyzers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

IR Contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)